27-06-2018
Once again this year, Inke has attended the Respiratory Drug Delivery (RDD) Symposium that took place in Tucson, Arizona from 22 to 26 April.
This prestigious international symposium is held annually and is the leading event in the innovation of both drug administration and applications used in the treatment of diseases of the respiratory system.
This is the second year running that Inke has attended the RDD as a sponsoring exhibitor with two scientific posters.
The two posters which were presented, and which were also published in the scientific book of the RDD Symposium given to all the attendees, were:
Inke is the NuPharm Group company focused on the development and manufacture of active pharmaceutical ingredients (APIs) for use in respiratory diseases, mainly for the treatment of COPD (chronic obstructive pulmonary disease).
See more at Inke - RDD Symposium
During 2023, Inke has increased its production capacity by making a significant investment in new reactors and clean rooms. This initiative has been carried out with the support of ACCIÓ from the Generalitat de Catalunya.
Transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity.
